Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure of the short-form ATP-phosphoribosyltransferase from Acinetobacter baumannii reveals the presence of a novel Mg<sup>2+</sup> sequestering and storage site.

Biochimica et biophysica acta. Proteins and proteomics·2026
Same author

Structural Basis for Single-Site Cleavage of Lactoferrin by Diverse Proteases for Prolonged Antibacterial Action: Structure of the Chymotrypsin-Cleaved Lactoferrin C-Lobe.

Proteins·2026
Same author

Targeting Resistance Vulnerabilities of Clinical ESKAPE Isolates Using Lactoferrin and Its Functional Fragments.

Current microbiology·2026
Same author

Backbone resonance assignment of mucoricin: a step towards structural insights into mucor pathogenesis.

Biomolecular NMR assignments·2026
Same author

Long term outcomes of the Indian childhood cancer survivorship (C2S) cohort: a multicentre study (2016-2024).

The Lancet regional health. Southeast Asia·2026
Same author

Structural insights into MERS and SARS coronavirus membrane proteins.

Communications biology·2025

Related Experiment Video

Updated: May 31, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

New weapons in the war on tuberculosis.

Sujata Sharma1, Mark A Yoder

  • 1Family Medicine, Resurrection Medical Center, Chicago, IL, USA.

American Journal of Therapeutics
|July 12, 2011
PubMed
Summary
This summary is machine-generated.

New tuberculosis treatments and vaccines are emerging to combat drug resistance and improve patient outcomes. This expanded arsenal offers hope for overcoming this persistent global health threat.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Experiment Videos

Last Updated: May 31, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Vaccinology

Background:

  • Tuberculosis (TB) remains a significant global health challenge, exacerbated by long treatment durations, drug resistance, and TB-HIV coinfection.
  • Current TB treatment regimens face limitations including toxicity and the slow development of new therapeutic agents and effective vaccines.
  • The emergence of drug-resistant Mycobacterium tuberculosis strains necessitates novel strategies for disease control.

Purpose of the Study:

  • To review recent advancements in tuberculosis treatment and vaccine development.
  • To highlight new drug candidates and vaccine strategies targeting Mycobacterium tuberculosis.
  • To discuss the potential of these innovations in overcoming treatment challenges and drug resistance.

Main Methods:

  • Review of recent scientific literature on tuberculosis therapeutics and vaccines.
  • Analysis of emerging drug discovery pipelines for novel anti-TB agents.
  • Examination of ongoing clinical trials for new TB vaccines and medications.

Main Results:

  • New anti-TB medications are in development, offering improved efficacy against resistant strains and potentially shorter treatment durations.
  • Novel vaccine candidates, including modified mycobacterial components, are progressing through clinical trials.
  • Strategies to optimize cost-effectiveness of current treatments, such as tailored therapy duration, are being explored.

Conclusions:

  • A new generation of anti-tuberculosis drugs and vaccines is poised to significantly impact global TB control efforts.
  • These advancements promise to address challenges posed by drug resistance and improve the safety and effectiveness of TB therapy.
  • The development of novel interventions offers a critical opportunity to combat tuberculosis and reduce its global burden.